Document
... Distribution in extracellular space Elimination unchanged in kidney Variable elimination kinetics and therefore variable half-lives of elimination ranging from hours to days. ...
... Distribution in extracellular space Elimination unchanged in kidney Variable elimination kinetics and therefore variable half-lives of elimination ranging from hours to days. ...
Clobazam (Onfi®) - Texas Department of State Health Services
... Excretion: Clobazam is 82% renally excreted. It has elimination half-life of 36-42 hours. Clobazam metabolite (N-desmethylclobazam) has 71-82 hours of half-life. ...
... Excretion: Clobazam is 82% renally excreted. It has elimination half-life of 36-42 hours. Clobazam metabolite (N-desmethylclobazam) has 71-82 hours of half-life. ...
Tritace - Product Information
... Blood concentrations of ramipril and ramiprilat increase with increased dose, but are not strictly doseproportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2.5 - 20 mg dose range. The absolute bioavailabilities of ramipril and ramiprilat were 28 % and 44 %, respective ...
... Blood concentrations of ramipril and ramiprilat increase with increased dose, but are not strictly doseproportional. The 24-hour AUC for ramiprilat, however, is dose-proportional over the 2.5 - 20 mg dose range. The absolute bioavailabilities of ramipril and ramiprilat were 28 % and 44 %, respective ...
Expert position paper on the use of proton pump inhibitors in
... with PPIs.7 Patients receiving PPIs had reduced antiplatelet effect of ASA, as shown by greater residual platelet aggregation responses. However, interaction between PPI and ASA is controversial.8 Potential clinical implications of these findings were explored by a registry study in a large populati ...
... with PPIs.7 Patients receiving PPIs had reduced antiplatelet effect of ASA, as shown by greater residual platelet aggregation responses. However, interaction between PPI and ASA is controversial.8 Potential clinical implications of these findings were explored by a registry study in a large populati ...
Corticosteroids in sports-related injuries: Friend or Foe
... history of glaucoma.29 Sub-capsular cataract formation has been strongly associated with prednisolone administration and may be related to covalent binding between glucocorticoid and the protein matrices of the lens, resulting in its destabilisation.30,31 Nitrogen retention, bone formation and colla ...
... history of glaucoma.29 Sub-capsular cataract formation has been strongly associated with prednisolone administration and may be related to covalent binding between glucocorticoid and the protein matrices of the lens, resulting in its destabilisation.30,31 Nitrogen retention, bone formation and colla ...
Your Guide to Taking
... check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems. Tell your healthcare provider right away if you experience yellowing of your skin or the white part of your eyes, nausea, vomiting, dark urine, or change in your sleep patt ...
... check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems. Tell your healthcare provider right away if you experience yellowing of your skin or the white part of your eyes, nausea, vomiting, dark urine, or change in your sleep patt ...
AusPAR: Retigabine - Therapeutic Goods Administration
... retigabine, but also in other excitable cells. KCNQ2, KCNQ3 and KCNQ5 are the dominant forms expressed in neural tissues, but these channels are also expressed in the urinary bladder (all forms, but predominantly KCNQ3), intestine (KCNQ3 in combination with KCNQ1) and skeletal muscles (KCNQ5). KCNQ4 ...
... retigabine, but also in other excitable cells. KCNQ2, KCNQ3 and KCNQ5 are the dominant forms expressed in neural tissues, but these channels are also expressed in the urinary bladder (all forms, but predominantly KCNQ3), intestine (KCNQ3 in combination with KCNQ1) and skeletal muscles (KCNQ5). KCNQ4 ...
AFREZZA® | Inhaled Insulin | Fast Acting Insulin | A1C Control
... Before initiating therapy with AFREZZA, evaluate all patients with a medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease. Acute bronchospasm has been observed following AFREZZA dosing in patients with asthma and patients with COPD. In a study of ...
... Before initiating therapy with AFREZZA, evaluate all patients with a medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease. Acute bronchospasm has been observed following AFREZZA dosing in patients with asthma and patients with COPD. In a study of ...
Poster presentation
... fact that about 60% of the Nigerian population use the private sector. In this study, baseline studies showed most of the facilities recorded very low percentage of prescriptions in the recommended dose. It is noteworthy that one of the facilities had not even one correct prescription. For drugs tha ...
... fact that about 60% of the Nigerian population use the private sector. In this study, baseline studies showed most of the facilities recorded very low percentage of prescriptions in the recommended dose. It is noteworthy that one of the facilities had not even one correct prescription. For drugs tha ...
Octroflex solution for injection ENG SmPC
... compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index should therefore be used with caution ...
... compounds known to be metabolised by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. Since it cannot be excluded that octreotide may have this effect, other drugs mainly metabolised by CYP3A4 and which have a low therapeutic index should therefore be used with caution ...
Renal hemodynamics and reduction of proteinuria by a vasodilating
... Abbreviation is PRA, plasma renin activity. a P < 0.05 compared to placebo and values under dilevalol ...
... Abbreviation is PRA, plasma renin activity. a P < 0.05 compared to placebo and values under dilevalol ...
summary of product characteristics
... Dosage adjustment and maintenance The dose of buprenorphine should be increased progressively according to the clinical effect of the individual patient and should not exceed a maximum single daily dose of 24 mg. The dosage is titrated according to reassessment of the clinical and psychological stat ...
... Dosage adjustment and maintenance The dose of buprenorphine should be increased progressively according to the clinical effect of the individual patient and should not exceed a maximum single daily dose of 24 mg. The dosage is titrated according to reassessment of the clinical and psychological stat ...
Product Monograph Template - Standard
... or symptoms of acute hepatitis, in particular if drug-related hypersensitivity is suspected or with increased liver transaminases combined with rash or other systemic symptoms of potential hypersensitivity (e.g. pruritic rash, eosinophila or elevated IgE). Caution should also be used when administer ...
... or symptoms of acute hepatitis, in particular if drug-related hypersensitivity is suspected or with increased liver transaminases combined with rash or other systemic symptoms of potential hypersensitivity (e.g. pruritic rash, eosinophila or elevated IgE). Caution should also be used when administer ...
Prescribing Information
... of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask som ...
... of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents. These infections may be mild to severe. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask som ...
Calcium and Beta Receptor Antagonist Overdose
... 4 L/kg.12 The more lipid soluble compounds require hepatic biotransformation prior to secretion and can therefore accumulate with hepatic insufficiency. In contrast, the water-soluble compounds are excreted by the kidney and can accumulate with renal insufficiency. Esmolol is water soluble but does ...
... 4 L/kg.12 The more lipid soluble compounds require hepatic biotransformation prior to secretion and can therefore accumulate with hepatic insufficiency. In contrast, the water-soluble compounds are excreted by the kidney and can accumulate with renal insufficiency. Esmolol is water soluble but does ...
Revised: October 2016 AN: 00542/2016 SUMMARY OF PRODUCT
... faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adve ...
... faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions generally occur within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adve ...
Navigating Acid Suppression Options
... When should higher PPI doses be used? • Double dose PPI therapy may be considered if standard doses are not effective (e.g. after 2-4 weeks of therapy).2,7 Double dose PPI should be reassessed after 4-8 weeks of therapy.2 • Lack of response to standard dose PPI warrants reassessment of the diagnosis ...
... When should higher PPI doses be used? • Double dose PPI therapy may be considered if standard doses are not effective (e.g. after 2-4 weeks of therapy).2,7 Double dose PPI should be reassessed after 4-8 weeks of therapy.2 • Lack of response to standard dose PPI warrants reassessment of the diagnosis ...
Medicine - Semantic Scholar
... Lengthy exposure to quinolone-containing triple therapy in Helicobacter pylori eradication leads to the development of drug resistance. Sequential therapy with a quinolone and metronidazole -containing regimen appears to be an effective treatment option. This randomized controlled trial aimed to com ...
... Lengthy exposure to quinolone-containing triple therapy in Helicobacter pylori eradication leads to the development of drug resistance. Sequential therapy with a quinolone and metronidazole -containing regimen appears to be an effective treatment option. This randomized controlled trial aimed to com ...
Public Assessment Report Paediatric data Ciloxan Ciprofloxacin
... Children 1 year of age and above The dosage is the same as for adults. Children from birth to 1 month of age For the treatment of bacterial conjunctivitis: Instill one drop into the conjunctival sac(s) of the affected eye(s) three times daily for four days. Safety and effectiveness of CILOXAN 3 mg/m ...
... Children 1 year of age and above The dosage is the same as for adults. Children from birth to 1 month of age For the treatment of bacterial conjunctivitis: Instill one drop into the conjunctival sac(s) of the affected eye(s) three times daily for four days. Safety and effectiveness of CILOXAN 3 mg/m ...
: " ¯ CONCERTA™ International Non
... Pregnancy and Lactation Pregnancy: The safety of methylphenidate for use during human pregnancy has not been established. No studies are available on the use of CONCERTA in pregnant women. CONCERTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fet ...
... Pregnancy and Lactation Pregnancy: The safety of methylphenidate for use during human pregnancy has not been established. No studies are available on the use of CONCERTA in pregnant women. CONCERTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fet ...
Phenytoin Dosing Guidelines
... (3) Changes in the daily maintenance dose should be made in small increments (30-100mg maximum). Sample serum levels 7 to 10 days following each dosage change to assess the trend. Steady state is usually achieved after 10-14 days, however, it may be much longer than this in some patients. (4) Once t ...
... (3) Changes in the daily maintenance dose should be made in small increments (30-100mg maximum). Sample serum levels 7 to 10 days following each dosage change to assess the trend. Steady state is usually achieved after 10-14 days, however, it may be much longer than this in some patients. (4) Once t ...
Accelerated Refractive Performance
... WAVE® / ALLEGRETTO WAVE® Eye-Q Excimer Laser System are contraindicated if any of the following conditions exist. Potential contraindications are not limited to those included in this list: pregnant or nursing women; patients with a diagnosed collagen vascular, autoimmune or immunodeficiency disease ...
... WAVE® / ALLEGRETTO WAVE® Eye-Q Excimer Laser System are contraindicated if any of the following conditions exist. Potential contraindications are not limited to those included in this list: pregnant or nursing women; patients with a diagnosed collagen vascular, autoimmune or immunodeficiency disease ...
A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in
... [13, 14]. Anecdotal reports suggest that linezolid may be an effective option to treat complicated cases of MDR/XDR-TB. However, serious concerns have been raised regarding safety and tolerability. Results of the five studies available with more than one case described suggest that adverse events ma ...
... [13, 14]. Anecdotal reports suggest that linezolid may be an effective option to treat complicated cases of MDR/XDR-TB. However, serious concerns have been raised regarding safety and tolerability. Results of the five studies available with more than one case described suggest that adverse events ma ...
NORVIR® Capsules
... antiretroviral drugs (see Table 3). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering NORVIR to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Increa ...
... antiretroviral drugs (see Table 3). There may be an increased risk for transaminase elevations in patients with underlying hepatitis B or C. Therefore, caution should be exercised when administering NORVIR to patients with pre-existing liver diseases, liver enzyme abnormalities, or hepatitis. Increa ...
Ofloxacin
Ofloxacin is a synthetic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone.Ofloxacin was first patented in 1982 (European Patent Daiichi) and received approval from the U.S. Food and Drug Administration (FDA) on December 28, 1990. Ofloxacin is sold under a wide variety of brand names as well as generic drug equivalents, for oral and intravenous administration. Ofloxacin is also available for topical use, as eye drops and ear drops (marketed as Ocuflox and Floxin Otic respectively in the United States and marketed as Optiflox, eylox respectively in Jordan and Saudi Arabia).Ofloxacin is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin.Ofloxacin has been associated with adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); tendon damage may manifest long after therapy had been completed, and, in severe cases, may result in lifelong disabilities.